CN1985851A - Lipoid microsphere injection containing toad cake extract and its preparing method - Google Patents
Lipoid microsphere injection containing toad cake extract and its preparing method Download PDFInfo
- Publication number
- CN1985851A CN1985851A CNA2006100474037A CN200610047403A CN1985851A CN 1985851 A CN1985851 A CN 1985851A CN A2006100474037 A CNA2006100474037 A CN A2006100474037A CN 200610047403 A CN200610047403 A CN 200610047403A CN 1985851 A CN1985851 A CN 1985851A
- Authority
- CN
- China
- Prior art keywords
- venenum bufonis
- lipoclastic
- oil
- injection
- microsphere injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 61
- 239000007924 injection Substances 0.000 title claims abstract description 61
- 239000000284 extract Substances 0.000 title claims abstract description 19
- 239000004005 microsphere Substances 0.000 title claims description 58
- 238000000034 method Methods 0.000 title claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 41
- 238000002360 preparation method Methods 0.000 claims abstract description 25
- 239000004094 surface-active agent Substances 0.000 claims abstract description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 54
- 239000003921 oil Substances 0.000 claims description 46
- 235000019198 oils Nutrition 0.000 claims description 46
- 239000000839 emulsion Substances 0.000 claims description 31
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 25
- 239000000787 lecithin Substances 0.000 claims description 25
- 235000010445 lecithin Nutrition 0.000 claims description 25
- 229940067606 lecithin Drugs 0.000 claims description 25
- 210000003022 colostrum Anatomy 0.000 claims description 16
- 235000021277 colostrum Nutrition 0.000 claims description 16
- 239000002609 medium Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 13
- 239000003549 soybean oil Substances 0.000 claims description 12
- 235000012424 soybean oil Nutrition 0.000 claims description 12
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 11
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 11
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 11
- 239000005642 Oleic acid Substances 0.000 claims description 11
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 11
- 239000004615 ingredient Substances 0.000 claims description 11
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 11
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 11
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 11
- 229920000053 polysorbate 80 Polymers 0.000 claims description 11
- 241000269417 Bufo Species 0.000 claims description 9
- -1 fatty acid ester Chemical class 0.000 claims description 9
- 210000000582 semen Anatomy 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 239000012567 medical material Substances 0.000 claims description 7
- 229920001983 poloxamer Polymers 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 150000003904 phospholipids Chemical group 0.000 claims description 6
- 229920000136 polysorbate Polymers 0.000 claims description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical class C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 5
- 239000008346 aqueous phase Substances 0.000 claims description 5
- 229960003964 deoxycholic acid Drugs 0.000 claims description 5
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 5
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 5
- 239000007764 o/w emulsion Substances 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 4
- 235000019485 Safflower oil Nutrition 0.000 claims description 4
- 239000010775 animal oil Substances 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000009969 fructus bruceae Substances 0.000 claims description 4
- 239000002480 mineral oil Substances 0.000 claims description 4
- 235000010446 mineral oil Nutrition 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 235000005713 safflower oil Nutrition 0.000 claims description 4
- 239000003813 safflower oil Substances 0.000 claims description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- 239000008158 vegetable oil Substances 0.000 claims description 4
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004380 Cholic acid Substances 0.000 claims description 3
- 150000001654 bufanolides Chemical class 0.000 claims description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 3
- 229960002471 cholic acid Drugs 0.000 claims description 3
- 235000019416 cholic acid Nutrition 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 229960000502 poloxamer Drugs 0.000 claims description 3
- 230000003637 steroidlike Effects 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 2
- 229920002651 Polysorbate 85 Polymers 0.000 claims description 2
- RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical compound [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000013522 chelant Substances 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- IFRDBGYJSLDMHQ-UHFFFAOYSA-J magnesium;disodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;hydrate Chemical compound O.[Na+].[Na+].[Mg+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O IFRDBGYJSLDMHQ-UHFFFAOYSA-J 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 229940101027 polysorbate 40 Drugs 0.000 claims description 2
- 229940113124 polysorbate 60 Drugs 0.000 claims description 2
- 229940113171 polysorbate 85 Drugs 0.000 claims description 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 239000004519 grease Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 41
- 206010028980 Neoplasm Diseases 0.000 abstract description 17
- 230000001093 anti-cancer Effects 0.000 abstract description 7
- 210000004204 blood vessel Anatomy 0.000 abstract description 6
- 230000007794 irritation Effects 0.000 abstract description 4
- 230000000202 analgesic effect Effects 0.000 abstract description 3
- 231100000956 nontoxicity Toxicity 0.000 abstract 1
- 239000008215 water for injection Substances 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 230000004083 survival effect Effects 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 239000012071 phase Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 13
- 230000008859 change Effects 0.000 description 12
- 238000000605 extraction Methods 0.000 description 11
- 150000002632 lipids Chemical group 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 238000005360 mashing Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 206010058019 Cancer Pain Diseases 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 231100000111 LD50 Toxicity 0.000 description 7
- QZAYGJVTTNCVMB-UHFFFAOYSA-N Serotonin Natural products C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 238000000386 microscopy Methods 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000001568 sexual effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- 229930190011 Bufogenin Natural products 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000001871 Tachycardia Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- ATLJNLYIJOCWJE-CWMZOUAVSA-N bufogenin Chemical compound C=1([C@H]2C[C@H]3O[C@@]43[C@H]3[C@@H]([C@]5(CC[C@H](O)C[C@H]5CC3)C)CC[C@@]42C)C=CC(=O)OC=1 ATLJNLYIJOCWJE-CWMZOUAVSA-N 0.000 description 3
- 229950006858 bufogenin Drugs 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000010685 fatty oil Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000006794 tachycardia Effects 0.000 description 3
- 230000001550 time effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- VTTONGPRPXSUTJ-UHFFFAOYSA-N bufotenin Chemical compound C1=C(O)C=C2C(CCN(C)C)=CNC2=C1 VTTONGPRPXSUTJ-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 210000004709 eyebrow Anatomy 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000001033 granulometry Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229950002454 lysergide Drugs 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- KBKUJJFDSHBPPA-UHFFFAOYSA-N 5beta-hydroxylcinobufagin Natural products CC(=O)OC1C2OC22C3CCC4(O)CC(O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 KBKUJJFDSHBPPA-UHFFFAOYSA-N 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 241001415440 Bufo gargarizans Species 0.000 description 1
- 241000269420 Bufonidae Species 0.000 description 1
- 206010007270 Carcinoid syndrome Diseases 0.000 description 1
- SCULJPGYOQQXTK-OLRINKBESA-N Cinobufagin Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@H]5CC[C@H]4[C@@]43O[C@@H]4[C@@H]2OC(=O)C)C=CC(=O)OC=1 SCULJPGYOQQXTK-OLRINKBESA-N 0.000 description 1
- SCULJPGYOQQXTK-UHFFFAOYSA-N Cinobufagin Natural products CC(=O)OC1C2OC22C3CCC4CC(O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 SCULJPGYOQQXTK-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 241001415432 Duttaphrynus melanostictus Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000149140 Fejervarya limnocharis Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- KBKUJJFDSHBPPA-ZNCGZLKOSA-N cinobufotalin Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@@]5(O)CC[C@H]4[C@@]43O[C@@H]4[C@@H]2OC(=O)C)C=CC(=O)OC=1 KBKUJJFDSHBPPA-ZNCGZLKOSA-N 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000001936 exophthalmos Diseases 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000000380 hallucinogen Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 208000020470 nervous system symptom Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 206010030899 opisthotonus Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000000790 scattering method Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000010686 shark liver oil Substances 0.000 description 1
- 229940069764 shark liver oil Drugs 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000002708 spider venom Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to lipoid microspere injection composition containing liposoluble toad cake extract and its preparation process. The injection composition contains liposoluble toad cake extract 0.0001-5 wt%, liposoluble medium 1-30 wt%, surfactant 0.5-10 wt%, isoosmotic regulator 0.5-10 wt%, and water for the rest. The injection has anticancer and analgetic effects, less blood vessel irritation caused by toad cake, no toxicity on heart and capacity of raising the medicine concentration inside tumor.
Description
Technical field
The present invention relates to medical technical field, exactly it is a kind of lipide microsphere injection (oil in water emulsion) and preparation method that contains the Venenum Bufonis lipoclastic.
Background technology
For many years, though people have carried out many effort and obtained bigger progress, the harm of tumor up to now still fails effectively to be contained.Have data to show, 2002 domestic because of malignant tumor and the lethal number of cancer account for dead population's then 25.37%, and tumor has become first killer of harm humans health.Over the past two years, the morbidity of tumor was in rising trend, and age of onset also obviously moved down from average 55 years old.Can foretell that in from now on two, 30 years, the sickness rate of cancer and mortality rate will be the trend that continues rising.
Cancerous pain is the most common and symptom the most rambunctious of cancer patient, also is the key factor that influences patients ' life quality.China has cancer patient 2,000,000 now, annual New Development patient 1,600,000, and the cancer pain incidence rate is 51.5%.The World Health Organization (WHO) has set up World Health Organization (WHO) cancer pain treatment committee in nineteen eighty-two, and proposes to reach in 2000 the target that " makes cancer patient not bitterly " in the worldwide.Yet about 30%~50% cancer pain patient does not still obtain satisfied alleviation at present regrettably.At present, the key factor that life quality is effectively carried out, influenced to cancer pain as the anticancer plan of influence has been subjected to extensive attention, and the correlational study of cancerous pain has become global important subject.The scheme of " three ladder medicine analgesias " cancer pain control that application WHO widelys popularize, though curative effect is more definite, life-time service analgesics toxic and side effects is big, and addiction, dependency are strong, and be subjected to the restriction of patient tolerability, cause part patient analgesic effect not good enough.
Because most antitumor drug untoward reaction are serious, body and mind to the patient in therapeutic process causes very major injury, therefore how when improving curative effect of medication, alleviate the patient suffering, reduce the zest and the toxicity of medicine, thereby improve patient's life quality, the life that prolongs the patient as far as possible becomes new direction and the emphasis of present antitumor drug research gradually.Chinese medicine has its unique effect in the oncotherapy field, no matter suppress or killing tumor cell aspect, still postoperative conditioning, alleviate put, chemotherapy adverse effect, improve sings and symptoms, important effect has all been brought into play in aspects such as raising life quality.
Venenum Bufonis has another name called Bufo siccus eyebrow fat (" property of medicine opinion "), Bufo siccus eyebrow shortcake (" Japan hanako materia medica "), toad slurry (" Xinjiang medical material "), Oviductus Ranae shortcake (" Shandong Chinese medicine "), the Oviductus Ranae slurry (" the Chinese crude drug handbook), for the ear rear gland of Bufonidae animal Bufo siccus Bufo Bufo gargarizans Cantor or Bufo melanostictus Bufo melanostictusSchneide etc. and the white serosity of skin gland secretion, form through dry processing.The property sweet suffering, temperature (also have medical book to propose the Venenum Bufonis flavor and be hot cool viewpoint), poisonous.Can detoxify detumescence, heart tonifying, pain relieving.The treatment skin ulcer, carbuncle, diseases such as carbuncle on the back.Bufo siccus and related preparations treatment tumor have very long history in China.Just putting down in writing in first monograph on materia medica Shennong's Herbal of China: " the Rana limnocharis acrid in the mouth is cold, main that gas, and the hard blood of broken lump, carbuncle, the erosion of vulva, that obeys does not fever ".
Modern study shows and comprises the number of chemical composition in the Bufo siccus body, can be divided into two big classes by the difference of dissolution properties, and fat-soluble part accounts for 20%, has the steroidal structure, is referred to as bufanolide class (Bufosterol).Water-soluble portion is a certain amount of indoles alkaloid, and part polysaccharide, organic acid and aminoacid etc.
Studies confirm that the Venenum Bufonis anticancer effective component mostly is fat-soluble compound, wherein bufogenin, Toadpoison Medicine, cinobufotalin content is more, activity is stronger.The pharmacological action and the molecular pharmacology Study on Mechanism thereof anticancer, that alleviate cancer pain of Venenum Bufonis liposoluble constituent have become in recent years the focus and the focus of research both at home and abroad.
Toadpoison Medicine R
Cinobufacin OCOCH
3
Bufogenin H
Pharmaceutical research shows that Venenum Bufonis main mechanism anticancer, that alleviate cancer pain is: the biosynthesis of (1) anticancer DNA and RNA.(2) mitochondrion and the rough surface endoplasmic reticulum of destruction oncocyte.(3) inducing cancer cell differentiation, apoptosis.(4) value of raising cAMP and cAMP/cGMP.(5) improve mice serum IgG and total white blood cells.(6) strengthen macrophage phagocytic effect, the stimulation body release antitumor cell factor.Renewal studies show that Toadpoison Medicine can suppress tumor vascular endothelium and blood vessel hyperplasia, compares with traditional oncotherapy, suppresses the tumor tissues angiogenesis drug and is primarily aimed at the new vessels that has started, so have specificity.Simultaneously it can also human body immunity improving power, alleviates the toxicity of chemotherapy, reduces the cancer pain incidence rate, and enhancing body is to the toleration of radiotherapy, chemotherapy, and in optimal dose, toxicity is minimum.But the Venenum Bufonis liposoluble extract is widely distributed in vivo, causes allergic reaction easily after the intravenous injection, has zest for blood vessel, can cause heart condition reactions such as ventricular premature contraction simultaneously.
HUACHANSU ZHUSHEYE, Venenum Bufonis Injection development listing are early, with new drug approval standard at that time, only require that it provides stable repeatably composition as quality control standard, so be that to be no less than 0.50% (mg/ml) in 5-hydroxy tryptamine indoles alkaloid content be quality control standard.Indoles alkaloid class composition is proved the report that antitumor action is studied in the Bufo siccus but do not see so far, on the contrary, give birth to the generation that too much 5-hydroxy tryptamine can cause carcinoid syndrome in the tumor patient body, clinical manifestation is the congested flushing of women's head-ornaments portion paroxysmal, tachycardia and hypertension, also can cause dyspnea, asthma, the patient who has can cause intractable diarrhea.Bufotenine is the derivant of 5-hydroxy tryptamine, and pharmacological action is similar to the hallucinogen LSD (lysergicaciddiethylamide).Have lower content to distribute in the human body, but content detection is negative in urine, and excretion obviously raise in autism or obsession patient's the urine.Therefore it is still not improper to do the Quality Control composition of medicine with 5-hydroxy tryptamine, bring potential risk but also use for the Venenum Bufonis clinical safety.
The special physicochemical property and the hypotoxicity of lipomul have determined it to can be used as fat-soluble medicine, particularly the good carrier of cancer therapy drug, anaesthetic and anti-inflammatory drug.The normal method that adopts is the lipid core part that pharmaceutical pack is wrapped in lipomul because this structure also is similar to microsphere, so lipid microsphere (LipidMicrosphere, title LM) is also arisen at the historic moment.It is generally acknowledged that lipid microsphere is by medicine is dissolved in the fatty oil, and after phospholipid emulsifying is scattered in water, make, be a kind of be soft substrate and the microparticulate system sealed by immobilized artificial membrane with fatty oil, mean diameter is about 200nm.
LM has many physical chemistry and advantage biologically: (1) is the good carrier of fat-soluble medicine, has avoided the use of organic solvent.(2) quite a few drug distribution is in oil phase or oil-water interfacial film; change responsive medicine for facile hydrolysis or to pH; this " isolation " can protect medicine to exempt from destruction, avoided simultaneously contacting with the direct of body fluid, reduced issuable part of medicine self and blood vessel irritation.(3) particulate carrier can be concentrated contained medicine and be transported to specific part release and the performance curative effect.The small particle of particle diameter about 200nm can be engulfed by the phagocyte of the reticular tissue system of body and be trapped in reticular tissue system (as liver, lung etc.), and be significant to treatment for cancer.
This research will be developed the Venenum Bufonis novel form with the effect of medicine bomb targeted therapy--Venenum Bufonis lipide microsphere injection, reduce medicine for blood vessel irritation, avoid effective ingredient to be absorbed by heart, improve medicine tumor bulk concentration.This will reduce the cancer pain incidence rate to giving full play to its anti-tumor activity undoubtedly, further promote and to promote Venenum Bufonis significant in Clinical Application.
Summary of the invention
The purpose of this invention is to provide a kind of lipide microsphere injection (oil in water emulsion) and preparation method that contains the Venenum Bufonis lipoclastic.
This injection comprises the Venenum Bufonis lipoclastic, fat-soluble medium, water and surfactant.Wherein the Venenum Bufonis lipoclastic is the bufanolide class (Bufosterol) with steroidal structure, and such material derives from the Venenum Bufonis medical material, perhaps directly extracts conversion via Bufo siccus, is perhaps prepared by synthetic.
The acceptable material of fat-soluble medium indication one big class physiology, no matter be mineral oil, vegetable oil, animal oil, quintessence oil or artificial oil, or its mixture.Therefore, fat-soluble medium is in order to refer to the very material of different chemical character that has of a wide region.With type or functional classification oil the time, as mineral oil source from oil and comprise fat or the cerul hydrocarbon, aromatic hydrocarbon or blended fat and aromatic radical hydrocarbon.The oil such as the refined paraffin wax wet goods that in the mineral oil classification, also comprise petroleum derivation.In the vegetable oil classification, oil is mainly derived from seed or nut, and comprises drying oil such as Semen Lini and Oleum Verniciae fordii; Semi-drying oil such as safflower oil and soybean oil; Non-drying oil such as Oleum Ricini, Oleum Gossypii semen and Oleum Cocois and the soap stock that can be used as such as Petiolus Trachycarpi oil and Oleum Cocois.In the animal oil classification, oil is usually from as sebum, Adeps Sus domestica and stearic fat.Aqueous animal oil comprises fish oil, oleic acid, spermaceti wet goods.They contain abundant fatty acid usually.Comprise some vegetable oil, as olive oil, Oleum Gossypii semen, corn oil and Oleum Arachidis hypogaeae semen also comprise some special fish oil, and they are used as medicine widely owing to be rich in vitamin, as the morrhua liver, shark liver oil etc.Aqueous fatty oil such as single, double, triglyceride, or its mixture is preferred oil.According to the present invention, the triglyceride of medium chain also are useful oil.Be preferably long-chain fat acid glyceride, medium chain length fatty acid triglyceride, and composition thereof.
Used surfactant can be any surfactant, is generally phospholipid, polyoxyethylene sorbitan fatty acid ester (tween, Tween), the poloxalkol class (pluronic, Poloxamer, Pluronic), enuatrol, oleic acid, cholic acid, sodium cholate, deoxycholic acid, sodium deoxycholate and composition thereof.Described phospholipid is selected from lecithin, fabaceous lecithin, and composition thereof.Described tween is selected from polysorbas20, polysorbate40, and polysorbate60, Tween 80, polysorbate85, and composition thereof.Be preferably lecithin, fabaceous lecithin, enuatrol, oleic acid, Tween 80, pluronic F68, and composition thereof.
Typically, forming mass percent prescription of the present invention in preparation consists of:
Fat-soluble medium 1%~30%
Venenum Bufonis lipoclastic 0.0001%~5%
Surfactant 0.5%~10%
Isoosmotic adjusting agent 0.5%~10%
All the other are water for injection
If desired, also can add multiple additives in the compositions.As containing metal-chelator.The common metal chelating agen is a disodiumedetate, calcium disodium chelate, ethylenediamine tetraacetic acid disodium magnesium salt and composition thereof.Metal-chelator is about 0% to about 1% in the preparation consumption.
The present invention also relates to contain the preparation method of the lipide microsphere injection and the oil in water emulsion of Venenum Bufonis lipoclastic.Comprise in the following steps one or more:
1. the powder of Venenum Bufonis lipoclastic ultramicro powder suspension or ultra micro is added to the blank Emulsion that does not contain the Venenum Bufonis lipoclastic or contain in the Emulsion of part Venenum Bufonis lipoclastic through the high pressure homogenize process mixed Venenum Bufonis lipoclastic lipide microsphere injection.
The heating of Venenum Bufonis lipoclastic and fat-soluble medium is mixed 2., treat that effective ingredient is dissolved in fat-soluble medium after, by filtering or the centrifugal impurity of removing, redispersion prepares colostrum at aqueous phase through high-speed stirred.
With Venenum Bufonis lipoclastic and surfactant dissolves in organic solvent, remove organic solvent then, surplus materials is mixed with fat-soluble medium heating, redispersion passes through high-speed stirred and prepares colostrum at aqueous phase.
4. the preparation method of said preparation mainly comprises high-speed stirred process and high pressure homogenize process.
5. the high-pressure rotary sterilization is adopted in the sterilization of preparation.
This research will be prepared the Venenum Bufonis novel form with the effect of medicine bomb targeted therapy--Venenum Bufonis lipide microsphere injection, the clinical anticancer analgesic that is used for, this injection will reduce the blood vessel irritation of Venenum Bufonis, avoid effective ingredient to be absorbed by heart, improve medicine tumor bulk concentration.
Description of drawings:
Fig. 1 is the lipid microsphere structural representation.
Fig. 2 is that different concentration ethanol is to extracting result's influence.
(wherein,
Expression extract dry thing middle finger index composition content and,
The expression index components rate of transform)
Fig. 3 is that the different grain size powder is to extracting result's influence.
(wherein,
Expression extract dry thing middle finger index composition content and,
The expression index components rate of transform)
Fig. 4 is for extracting return time to extracting result's influence.
(wherein, the expression index components rate of transform,
Expression extract dry thing middle finger index composition content and)
Fig. 5 is the mensuration of Venenum Bufonis extract apparent oil water partition coefficient (Log P).
Fig. 6 is the influence of Venenum Bufonis lipide microsphere injection effect HGC cell 24h to survival rate
(wherein,
Represent blank Emulsion group, expression
The expression negative control group,
Expression Venenum Bufonis lipid microsphere group)
Fig. 7 is the influence of Venenum Bufonis lipide microsphere injection effect A549 cell 24h to survival rate
(wherein,
Represent blank Emulsion group, expression
The expression negative control group,
Expression Venenum Bufonis lipid microsphere group)
Fig. 8 is the influence of Venenum Bufonis lipide microsphere injection effect U87 cell 24h to survival rate
(wherein,
Represent blank Emulsion group, ■ represents Venenum Bufonis lipid microsphere group)
Fig. 9 is the influence of Venenum Bufonis lipide microsphere injection effect U251 cell 24h to survival rate
(wherein,
Represent blank Emulsion group, ■ represents Venenum Bufonis lipid microsphere group)
The specific embodiment
The prescription preparation technology of Venenum Bufonis lipide microsphere injection
Prescription 1:
Semen Coicis oil 1-30g
Venenum Bufonis lipoclastic 0.0001g-5g
Lecithin 0.5-10g
Glycerol 0.5-10g
Water for injection adds to 100ml
Preparation method 1:
(1) lecithin, the glycerol of recipe quantity is added in an amount of water for injection 40-100 ℃ mix water; (2) the Venenum Bufonis lipoclastic is added in the Semen Coicis oil, be heated at 40-100 ℃ and must clarify oil phase through 0.45 μ m after effective ingredient dissolves fully; (3) will water and oil phase change in the tissue mashing machine after mixing, stirred for several minute 1-5 time, is prepared into colostrum; (4) get above-mentioned colostrum and add water for injection, regulate pH5-8, be transferred in the high pressure homogenizer to full dose, homogenize 1-10 time, the microscopy of taking a sample, to oil droplet below 0.5 μ m; (5) get homogenizing after the Emulsion embedding in infusion bottle, fill nitrogen, place the high-pressure rotary steriliser to sterilize.
Prescription 2:
Soybean oil 1-30g
Venenum Bufonis lipoclastic 0.0001g-5g
Fabaceous lecithin 0.5-10g
Glycerol 0.5-10g
Oleic acid 0.5-10g
Water for injection adds to 100ml
Preparation method 2:
(1) recipe quantity glycerol is added in an amount of water for injection 40-100 ℃ mix water; (2) with the Venenum Bufonis lipoclastic, fabaceous lecithin, oleic acid add in the soybean oil, are heated at 40-100 ℃ and must clarify oil phase through 0.45 μ m after effective ingredient dissolves fully; (3) will water and oil phase change in the tissue mashing machine after mixing, stirred for several minute 1-5 time, is prepared into colostrum; (4) get above-mentioned colostrum and add water for injection, regulate pH5-8, be transferred in the high pressure homogenizer to full dose, homogenize 1-10 time, the microscopy of taking a sample, to oil droplet below 0.5 μ m; (5) get homogenizing after the Emulsion embedding in infusion bottle, fill nitrogen, place the high-pressure rotary steriliser to sterilize.
Prescription 3:
Medium chain length fatty acid triglyceride 1-30g
Venenum Bufonis lipoclastic 0.0001g-5g
Fabaceous lecithin 0.5-10g
Glycerol 0.5-10g
Enuatrol 0.5-10g
Water for injection adds to 100ml
Preparation method 3:
(1) with recipe quantity glycerol, enuatrol add in an amount of water for injection 40-100 ℃ mix water, regulating water pH is 4-7; (2) with the Venenum Bufonis lipoclastic, fabaceous lecithin adds in the medium chain length fatty acid triglyceride, is heated at 40-100 ℃ and must clarifies oil phase through centrifugal after effective ingredient dissolves fully; (3) will water and oil phase change in the tissue mashing machine after mixing, stirred for several minute 1-5 time, is prepared into colostrum; (4) get above-mentioned colostrum and add water for injection, regulate pH5-8, be transferred in the high pressure homogenizer to full dose, homogenize 1-10 time, the microscopy of taking a sample, to oil droplet below 0.5 μ m; (5) get homogenizing after the Emulsion embedding in infusion bottle, fill nitrogen, place the high-pressure rotary steriliser to sterilize.
Prescription 4:
Oleum Fructus Bruceae 1-30g
Venenum Bufonis lipoclastic 0.0001g-5g
Fabaceous lecithin 0.5-10g
Glycerol 0.5-10g
Oleic acid 0.5-10g
Water for injection adds to 100ml
Preparation method 4:
(1) recipe quantity glycerol is added in an amount of water for injection 40-100 ℃ mix water; (2) with the Venenum Bufonis lipoclastic, fabaceous lecithin, oleic acid add in the Oleum Fructus Bruceae, are heated at 40-100 ℃ and must clarify oil phase through 0.45 μ m after effective ingredient dissolves fully; (3) will water and oil phase change in the tissue mashing machine after mixing, stirred for several minute 1-5 time, is prepared into colostrum; (4) get above-mentioned colostrum and add water for injection, regulate pH5-8, be transferred in the high pressure homogenizer to full dose, homogenize 1-10 time, the microscopy of taking a sample, to oil droplet below 0.5 μ m; (5) get homogenizing after the Emulsion embedding in infusion bottle, fill nitrogen, place the high-pressure rotary steriliser to sterilize.
Prescription 5:
Soybean oil 1-30g
Venenum Bufonis lipoclastic 0.0001g-5g
Fabaceous lecithin 0.5-10g
Glycerol 0.5-10g
Oleic acid 0.5-10g
EDTA-2Na 0-1g
Water for injection adds to 100ml
Preparation method 5:
(1) with recipe quantity glycerol, Tween 80, EDTA-2Na add in an amount of water for injection 40-100 ℃ mix water; (2) with the Venenum Bufonis lipoclastic, fabaceous lecithin, oleic acid add in the soybean oil, are heated at 40-100 ℃ and must clarify oil phase through 0.45 μ m after effective ingredient dissolves fully; (3) will water and oil phase change in the tissue mashing machine after mixing, stirred for several minute 1-5 time, is prepared into colostrum; (4) get above-mentioned colostrum and add water for injection, regulate pH5-8, be transferred in the high pressure homogenizer to full dose, homogenize 1-10 time, the microscopy of taking a sample, to oil droplet below 0.5 μ m; (5) get homogenizing after the Emulsion embedding in infusion bottle, fill nitrogen, place the high-pressure rotary steriliser to sterilize.
Prescription 6:
Soybean oil/medium chain length fatty acid triglyceride 1-30g
Venenum Bufonis lipoclastic 0.0001g-5g
Lecithin 0.5-10g
Glycerol 0.5-10g
F68 0.5-10g
EDTA-2Na 0-1g
Water for injection adds to 100ml
Preparation method 6:
(1) recipe quantity Venenum Bufonis lipoclastic is scattered in the Tween-80 solution, high speed agitator stirred for several minute, 1-5 time, use 1-10 (50-100MP of high pressure dispersing emulsification machine homogenize then, 20-100 ℃) medicine dispersion soln (2) with lecithin, the glycerol of recipe quantity and be preheated to 40-100 ℃ medicine dispersion soln and mix, change in the tissue mashing machine stirred for several minute over to, 1-5 time, disperse until each uniform ingredients; (3) in above-mentioned dispersion liquid, add 40-100 ℃ the soybean oil of being preheated to of recipe quantity, change in the tissue mashing machine, stirred for several minute, 1-5 time, until the oil phase homodisperse, the water for injection that adds 20-100 ℃ is to full dose; (4) get above-mentioned colostrum and add water for injection, regulate pH5-8, be transferred in the high pressure homogenizer to full dose, homogenize 1-10 time, the microscopy of taking a sample, to oil droplet below 0.5 μ m; (5) get homogenizing after the Emulsion embedding in infusion bottle, fill nitrogen, place the high-pressure rotary steriliser to sterilize.
Prescription 7:
Safflower oil 1-30g
Venenum Bufonis lipoclastic 0.0001g-5g
Lecithin 0.5-5g
Glycerol 0-5g
Tween-80 0-1g
Water for injection adds to 100ml
Preparation method 7:
(1) recipe quantity Venenum Bufonis lipoclastic is scattered in the Tween-80 solution, high speed agitator stirred for several minute, 1-5 time, use 1-10 (50-100MP of high pressure dispersing emulsification machine homogenize then, 20-100 ℃) medicine dispersion soln (2) with lecithin, the glycerol of recipe quantity and be preheated to 40-100 ℃ water for injection and mix, change in the tissue mashing machine stirred for several minute over to, 1-5 time, until each uniform ingredients disperse water; (3) water is added 40-100 ℃ the soybean oil of being preheated to of recipe quantity, change in the tissue mashing machine, stirred for several minute, 1-5 time, until the oil phase homodisperse, the water for injection that adds 20-100 ℃ is to full dose; (4) Venenum Bufonis lipoclastic ultramicro powder suspension being added blank Emulsion high speed stirs; (5) get above-mentioned colostrum and add water for injection, regulate pH5-8, be transferred in the high pressure homogenizer to full dose, homogenize 1-10 time, the microscopy of taking a sample, to oil droplet below 0.5 μ m; (6) get the embedding of Venenum Bufonis lipoclastic submicronized emulsion in infusion bottle, fill nitrogen, place the high-pressure rotary steriliser, sterilization.
Prescription 8:
Oil phase (the 5-30g of soybean oil/MCT)
Venenum Bufonis lipoclastic 0.0001g-5g
Lecithin 0.5-5g
Glycerol 0-5g
Enuatrol 0-1g
EDTA 0-1g
Water for injection adds to 100mL
Preparation method 8:
(1) glycerol for injection, enuatrol, EDTA, F68 are scattered in an amount of water for injection, are heated to 40-100 ℃ to the magnetic stirring apparatus to be stirred to whole dissolvings; (2) injection lecithin, Tween-80, be added in the mixing oil phase of forming by injection MCT, injection soybean oil, be heated to and be stirred to lecithin under 40-100 ℃ and dissolve fully, add the Venenum Bufonis lipoclastic, carry out high pressure homogenize.(3) oil phase is added to aqueous phase, places high-speed tissue mashing machine's stirred for several minute, 1-5 time.(4) regulate pH value to 4-9, the water for injection dilution is settled to recipe quantity, is transferred to the high pressure homogenizer homogenizing 3-10 time.(5) bottling, sealed cans nitrogen places the high-pressure rotary steriliser, sterilization.
In above listed prescription, the compositions, prepare 5 preparations in addition by above method, their quality percentage composition following (all the other are water):
| The Venenum Bufonis lipoclastic | 0.0001-5% |
| Soybean oil, safflower oil, Semen Coicis oil, Oleum Fructus Bruceae, medium chain length |
1%-30% |
| Lecithin, fabaceous lecithin | 0.5%-10% |
| Oleic acid, enuatrol | 0.5%-10% |
| Cholic acid, sodium deoxycholate | 0.5%-10% |
| Glycerol, sorbitol, mannitol, glucose | 0.5%-10% |
| EDTA | 0-1% |
| Poloxamer F68 | 0.5%-10 |
| Tween | |
| 80 | 0.5%-10% |
The Venenum Bufonis Study on extraction process
1 different concentration ethanol is to extracting result's influence
Choose Venenum Bufonis medical material fine powder, (1g: 10mL) the different proportion alcohol heating reflux is 1 hour, puts to room temperature sucking filtration, filtrate evaporate to dryness, the dry thing of filtrate and each vacuum drying of residue one day to adopt 10 times of amounts.Measure index sexual element content in the dry thing respectively.The results are shown in Figure 2.
Along with the increase of concentration of alcohol, the content of index components in dry extract increases, and 90% ethanol extract color and luster is near colourless as can be seen in appearance, and it is yellow that 70% ethanol extract then is.Also because 90% ethanol remove impurity ability is strong, the dry extraction amount is starkly lower than the dry thing of low concentration ethanol extraction simultaneously, so extract yield is minimum, the medicine rate of transform that calculates is minimum.Bibliographical information is arranged in addition, detect various toad spider toxin extract and chromatography purification thing to HL60 cell inhibitory effect intensity difference by cell viability, what its inhibitory action was the strongest is 80% alcohol reflux product.Take all factors into consideration, this test initial option 80% ethanol carries out the investigation of other indexs as extracting solvent.
2 different grain size powder are to extracting result's influence
Get three parts of different grain size Venenum Bufonis medicinal powders, adopt 10 times of amounts (1g: 10mL) 80% alcohol heating reflux is 1 hour, put to room temperature, sucking filtration, the filtrate evaporate to dryness, the dry thing of filtrate and each vacuum drying of residue one day are measured index sexual element content in the dry thing respectively.The results are shown in Figure 3.
The pulverizer that is adopted in this test operation at short notice can be with pulverizing medicinal materials below 60 orders, and wherein majority is distributed in the 80-100 order.Therefore we are only to the 60-80 order, and the 80-100 order reaches less than 100 purpose powder and carried out extracting investigation.The result shows that three kinds of scope powder do not have notable difference in the extraction result of 80% alcohol reflux after 1 hour.
3 extract return time to extracting result's influence
Choose Venenum Bufonis medical material fine powder, adopt 10 times of amounts (1g: 10mL) 80% alcohol heating reflux is 0.5,1,2 hour, put to room temperature, sucking filtration, the filtrate evaporate to dryness, the dry thing of filtrate and each vacuum drying of residue one day are measured index sexual element content in the dry thing respectively.The results are shown in Figure 4.No matter found out that by figure extraction time surpassed after 1 hour, be index sexual element content or its rate of transform does not all have significant change in the extract.Therefore determine that tentatively under the constant prerequisite of other extraction conditions, the alcohol reflux time is 1 hour.
4 single factors are investigated back extraction process demonstration test
Investigate the extraction process result of the test according to single factor, determine that tentatively Venenum Bufonis lipoclastic extraction process is: choose Venenum Bufonis medical material fine powder, (1g: 10mL) 80% alcohol heating reflux is 1 hour to adopt 10 times of amounts, put to room temperature, sucking filtration, filtrate evaporate to dryness, the dry thing vacuum drying of gained one day.Get three parts of Venenum Bufonis medical materials, carry out demonstration test, measure the index sexual element content and the rate of transform in the dry thing according to said extracted technology.The result shows that the extraction process repeatability is good, and the meansigma methods of extract yield index sexual element percentage composition is 27.5 4%, and rate of transform meansigma methods is 84.63%.
The single factor of table 1 is investigated back extraction process demonstration test
| Number 123 mean RSD (%) | Extract yield | Extract index composition percentage composition and (%) | The rate of transform | |||
| (%) 36.7 36.3 36.2 36.4 0.7 | B 7.05 7.06 7.13 7.08 0.6 | C 9.15 9.28 9.12 9.18 0.9 | R 11.52 11.38 11.42 11.44 0.6 | Σ 27.72 27.22 27.67 27.54 1.0 | (%) 85.0 84.6 84.3 84.63 0.4 | |
The mensuration of Venenum Bufonis lipide microsphere injection particle diameter and Zeta-potential
Particle diameter and particle size distribution are one of most important characteristics of lipid microsphere, the granularity requirements of used for intravenous injection lipid microsphere still there is not unified regulation at present, the general particle diameter of the product of having reported is even, on average less than 1 μ m, do not have to assemble and merge phenomenon, in 1 Emulsion liquid (0.05mL), no more than 2 of the emulsion droplet of 10-15 μ m does not have the emulsion droplet greater than 15 μ m.About the normal method that adopts of the emulsion droplet granulometry of lipid microsphere microscopic method, dynamic light scattering method, laser scattering method, Coulter counting method etc. are arranged at present.The particle size determination of LM is to adopt optical microscope and photon correlation spectroscopy method (Photon-Correlation Spectroscopy in this test, PCS), also claim dynamic light scattering principle (Dynamic light scatter, DLS, NicompTM PSS 380).
The operational approach of using NicompTM PSS 380 to carry out granulometry is: used the water for injection of 0.22 μ m microporous filter membrane to dilute about 5000 times in sample, put into sample cell immediately, (Intensity) is adjusted to about 300 with light intensity, and light source is HeNe laser (λ
0=633nm), room temperature when temperature in the operating parameter is made as mensuration begins to measure, and keeps measuring stopping to measure when Time history curve is tending towards straight line, preserves data.Experimental result is seen Fig. 5.
Embodiment 4
The mensuration of Venenum Bufonis lipide microsphere injection median lethal dose(LD 50)
Experiment material
1 laboratory animal: Kunming kind white mice, body weight (20 ± 2) g, male and female half and half.
2 experimental drugs and reagent
Venenum Bufonis lipide microsphere injection (crude drug content: 40mg/50ml); Blank Emulsion.
3 experimental techniques
Venenum Bufonis lipide microsphere injection stock solution by 1: 0.7 dilution proportion, is made into the solution of 4 concentration.Get 50 of 24 hours mices of fasting, per 10 one group, the 1-4 group is by the dilution solution tail vein injection of above difference, and the 5th group is the blank group, and injection capacity is the 0.24ml/10g body weight.Observe immediately after the administration, every subsequently 4h observes 1 time, and observe 1 every day behind the 24h, finishes until 14d.Observe various toxic reactions, central nervous system's symptom and other unusual performance; The death time and the number of elements of record dead animal.And in time dissect dead animal, and take out heart, lung, when finishing, experiment dissects all animals, take out heart, lung, normal saline flushing is placed in 10% formalin fixing, does pathological examination.
4 experimental results
The central nervous system's of Venenum Bufonis lipide microsphere injection high dose group acute toxicity shows as the tic of laboratory animal whole body, the appearance of part laboratory animal is tetanic, opisthotonus deadly; Respiratory system show as accelerated breathing; Cardiovascular system show as tachycardia; Symptoms such as visible in addition upper eyelid is sagging, exophthalmos and incontinence; In, low dose group central nervous system's performance is not obvious, most animals is in the state of reposing, sagging, the rapid breathing in upper eyelid, tachycardia.Dead animal carries out gross anatomy, the visible pulmonary of naked eyes congestion.Its approximate LD
50See Table 2.
Table 2: Venenum Bufonis lipide microsphere injection LD
50Measurement result
| Dosage (mg/kg) (d) | Dosage logarithm value (x) | Mortality rate (p) | Probit (y) | Weight (w) |
| 9.41 13.44 19.20 | 0.974 1.128 1.283 | 2/10(20%) 5/10(50%) 9/10(90%) | 4.16 5.0 6.28 | 4.90 6.39 3.43 |
Σ15.44 Σ14.72
Adopt and simplify the median lethal dose(LD 50) that the probability method is calculated the Venenum Bufonis lipide microsphere injection.
=2×0.1549(5-5.147)/(6.28-4.16)+1.128
=1.107
LD
50=10
-11.107=12.794mg/kg
=0.0689×0.56
=0.0216
LD
5095% average fiducial limit=LD
50± 4.5 * Sx
50* LD
50
=12.794±1.244mg/kg
The Venenum Bufonis lipide microsphere injection is to the influence of tumor cell survival rate
Medicine: Venenum Bufonis lipide microsphere injection (in crude drug 0.8mg/ml, medicament teaching and research room of Shenyang Pharmaceutical University provides)
Reagent: 1640, DMEM, FBS, CS, MTT
Cell line: HGC stomach carcinoma (human), A549 lung carcinoma (human), U87 astrocytoma (human), U251 astrocytoma (human)
Method (MTT colorimetry):
Take the logarithm the cell of trophophase with 10 * 10
4The density of/ml is added in 96 well culture plates, 37 ℃, 5%CO
2Cultivate 24h under the condition, after changing serum-free medium, the Venenum Bufonis lipide microsphere injection is diluted to variable concentrations with serum-free medium to add in the experimental port respectively, other establishes not dosing negative control and the blank Emulsion contrast of each respective concentration, and each concentration is established 5 multiple holes, continues to cultivate 24h, add MTT (final concentration 0.25%) after cultivation finishes and continue to hatch 3h, change DMSO100 μ l/ hole after hatching end, effect 10min surveys the absorbance A value at microplate reader 492nm place.Suppression ratio=(1-dosing group absorbance/blank group absorbance) * 100%.
Statistical method: adopt one-way ANOVA in conjunction with the difference (* P<0.05) between blank Emulsion of each concentration of dunnett test comparison and the culture fluid matched group; Adopt Independent sample t-test relatively administration group and the blank Emulsion matched group (#P<0.05) of respective concentration.
The result:
1, Venenum Bufonis lipide microsphere injection effect HGC cell 24h is to the influence of survival rate
As seen from Figure 6, the blank Emulsion pair cell of each concentration survival rate has some influences, but does not have significant difference, may cause more greatly owing to standard deviation.Compare with its Emulsion matched group, but 8 and 80 μ g/ml group significance reduces the survival rate of HGC.
2, Venenum Bufonis lipide microsphere injection effect A549 cell 24h is to the influence of survival rate
As seen from Figure 7, the blank Emulsion pair cell of each concentration survival rate has some influences, and 10 times of groups of blank Emulsion dilution can significantly suppress cell survival rate.Compare with its Emulsion matched group, but 8 and 80 μ g/ml group significance reduces the survival rate of A549.
3, Venenum Bufonis lipide microsphere injection effect U87 cell 24h is to the influence of survival rate
As seen from Figure 8, the blank Emulsion matched group of each concentration does not all influence the survival rate of U87, but 0.08,0.8,8,80 μ g/ml significances reduce cell survival rate, and maximum can suppress about 50%.
4, Venenum Bufonis lipide microsphere injection effect U251 cell 24h is to the influence of survival rate
As seen from Figure 9, dilute blank Emulsion 10
3, 10
4Survival rate that doubly can appreciable impact U251, but 0.08,0.8,8,80 μ g/ml significances reduce cell survival rate, and maximum can suppress about 40%.
Embodiment 6
Venenum Bufonis lipide microsphere injection mice acetic acid twisting test report
Equipment: 1ml syringe, balance, stopwatch.
Medicine: 0.7% acetum; Venenum Bufonis lipide microsphere injection (in crude drug 0.8mg/ml, medicament teaching and research room of Shenyang Pharmaceutical University provides)
Animal: Kunming kind white mice (18~22g).
Method: the investigation of (1) Venenum Bufonis lipide microsphere injection dose-effect relationship: white mice is divided into 8 groups at random, and 12 every group, the abdominal cavity gives the Venenum Bufonis lipide microsphere injection of variable concentrations, and the administration volume is 0.2ml/10g.Each Mus lumbar injection 0.7% acetum 0.2ml of 1h after the administration.Observe and write down the number of times that occurs writhing response in the 15min, calculate and turn round the body suppression ratio, carry out group difference relatively.(2) investigation of Venenum Bufonis lipide microsphere injection time-effect relationship: white mice is divided into 5 groups at random, every group 6, the abdominal cavity gives the Venenum Bufonis lipide microsphere injection, and dosage is the lowest dose level that significant difference is arranged with the solvent control group among the dose-effect result, and the administration volume is 0.2ml/10g.Each treated animal is injected 0.7% acetum 0.2ml at administration 0.5h, 1h, 1.5h, 2h, 2.5h pneumoretroperitoneum respectively, observes and write down the number of times that occurs writhing response in the 15min, calculates and turns round the body suppression ratio.
The result:
(1) mice acetic acid twisting method is investigated Venenum Bufonis lipide microsphere injection dose-effect relationship, as following table.
| Group | Dosage is (by giving birth to amount approximately, mg/ml) | Example number (only) | Turn round body number of times (X ± SD) in the 15min | Suppression ratio (%) |
| 1 2 | 0.4 0.16 | 12 12 | 6.33±4.479** 6.50±3.754** | 69.00 68.17 |
| 3 4 5 6 7 8 | 0.08 0.04 0.02 0.01 0.008 solvent control group | 12 12 12 12 12 12 | 7.17±4.549** 7.92±4.441** 9.25±5.446* 11.67±5.015 15.08±4.719 20.42±7.489 | 64.89 61.21 54.70 42.85 26.85 0.00 |
Annotate: compare * P<0.05, * * P<0.01 with the solvent control group.
(2) mice acetic acid twisting method is investigated Venenum Bufonis lipide microsphere injection time-effect relationship, as following table.
| Group | Dosage (by crude drug) mg/ml | Example number (only) | Time (h) | Turn round body number of times (X ± SE) in the 15min | Suppression ratio (%) |
| 1 2 3 4 5 | 0.02 solvent control group 0.02 solvent control group 0.02 solvent control group 0.02 solvent control group 0.02 solvent control group | 6 6 6 6 6 6 6 6 6 6 | 0.5 0.5 1.0 1.0 1.5 1.5 2.0 2.0 2.5 2.5 | 11.50±3.658 20.50±2.930 3.83±1.682 21.07±3.439 3.83±1.352 21.67±3.084 1.33±0.494 19.00±2.793 5.33±1.406 19.83±2.496 | 43.90 81.91 82.33 93.00 73.12 |
The result of the test of [conclusion] dose-effect relationship shows, all can significantly suppress the mouse writhing reaction that acetic acid causes when drug level is 0.4mg/ml, 0.16mg/ml, 0.08mg/ml, 0.04mg/ml, 0.02mg/ml.As calculated, the Venenum Bufonis lipide microsphere injection is to the median effective dose ED of mice acetic acid twisting reaction
50=0.0253mg/ml.The result of the test of time-effect relationship shows that behind the administration 2h, it is the most remarkable that the writhing response that Dichlorodiphenyl Acetate causes suppresses.
Claims (9)
1, a kind of lipide microsphere injection that contains the Venenum Bufonis lipoclastic is characterized in that: it comprises Venenum Bufonis lipoclastic, fat-soluble medium, water, surfactant and isoosmotic adjusting agent, and the mass percent of its composition is:
Fat-soluble medium 1% to 30%,
Venenum Bufonis lipoclastic 0.0001% to 5%,
Surfactant 0.5% to 10%,
Isoosmotic adjusting agent 0.5% to 10%,
Surplus is a water.
2, a kind of lipide microsphere injection that contains the Venenum Bufonis lipoclastic according to claim 1, it is characterized in that: described injection comprises the oil in water emulsion that contains the Venenum Bufonis lipoclastic that intravenous transfusion is used, and the compositions that constitutes this type of oil in water emulsion is identical with the compositions that constitutes lipide microsphere injection.
3, a kind of lipide microsphere injection that contains the Venenum Bufonis lipoclastic according to claim 1 and 2, it is characterized in that: described Venenum Bufonis lipoclastic is the bufanolide class (Bufosterol) with steroidal structure, such material derives from the Venenum Bufonis medical material, perhaps directly extract conversion, perhaps prepare by synthetic via Bufo siccus.
4, a kind of lipide microsphere injection that contains the Venenum Bufonis lipoclastic according to claim 1 and 2, it is characterized in that: also contain metal-chelator in the preparation, it forms mass percent is 0% to 1%, described metal-chelator (EDTA) is a disodiumedetate, calcium disodium chelate, ethylenediamine tetraacetic acid disodium magnesium salt or its mixture; Described isoosmotic adjusting agent is glycerol, sorbitol, mannitol, glucose, and composition thereof; Also contain sodium hydroxide in this external preparation, hydrochloric acid, and composition thereof.
5, a kind of lipide microsphere injection that contains the Venenum Bufonis lipoclastic according to claim 1 and 2, it is characterized in that: described fat-soluble medium is selected from mineral oil, vegetable oil, animal oil, quintessence oil and artificial oil, or its mixture; Described surfactant is selected from phospholipid, and polyoxyethylene sorbitan fatty acid ester (tween, Tween), poloxalkol class (pluronic, Poloxamer, Pluronic), enuatrol, oleic acid, cholic acid, sodium cholate, deoxycholic acid, sodium deoxycholate and composition thereof.
6, a kind of lipide microsphere injection that contains the Venenum Bufonis lipoclastic according to claim 1 and 2 is characterized in that: described grease separation is from safflower oil, the safranine caul-fat, soybean oil, Semen Maydis oil, Oleum Ricini, Oleum Gossypii semen, Oleum Cocois, Petiolus Trachycarpi oil, MCT Oil (MCT), Semen Coicis oil, Oleum Fructus Bruceae, and composition thereof; Wherein said phospholipid is selected from lecithin, fabaceous lecithin, synthetic phospholipid, or the arbitrary proportion mixture of above different size; Described tween is selected from polysorbas20, polysorbate40, polysorbate60, Tween 80, polysorbate85, or the arbitrary proportion mixture of above different size.
7, a kind of lipide microsphere injection that contains the Venenum Bufonis lipoclastic according to claim 1 and 2 is characterized in that: comprise following processing step: Venenum Bufonis lipoclastic ultramicro powder suspension or ultra-micro powder are added to the blank Emulsion that does not contain the Venenum Bufonis lipoclastic or contain in the Emulsion of part Venenum Bufonis lipoclastic through the high pressure homogenize process mixed Venenum Bufonis lipoclastic lipide microsphere injection.
8, a kind of lipide microsphere injection that contains the Venenum Bufonis lipoclastic according to claim 1 and 2, it is characterized in that: comprise following processing step: with Venenum Bufonis lipoclastic and surfactant dissolves in organic solvent, remove organic solvent then, surplus materials is mixed with fat-soluble medium heating, redispersion is at aqueous phase, after the process high-speed stirred prepares colostrum, carry out the high pressure homogenize process, the high-pressure rotary sterilization is adopted in the sterilization of preparation.
9, a kind of lipide microsphere injection that contains the Venenum Bufonis lipoclastic according to claim 1 and 2, it is characterized in that comprising following processing step: Venenum Bufonis lipoclastic and the heating of fat-soluble medium is mixed, after treating that effective ingredient is dissolved in fat-soluble medium, by filtering or the centrifugal impurity of removing, redispersion is at aqueous phase, after the process high-speed stirred prepares colostrum, carry out the high pressure homogenize process, the high-pressure rotary sterilization is adopted in the sterilization of preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100474037A CN1985851B (en) | 2006-08-07 | 2006-08-07 | Lipoid microsphere injection containing toad cake extract and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100474037A CN1985851B (en) | 2006-08-07 | 2006-08-07 | Lipoid microsphere injection containing toad cake extract and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1985851A true CN1985851A (en) | 2007-06-27 |
| CN1985851B CN1985851B (en) | 2012-01-25 |
Family
ID=38182878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006100474037A Expired - Fee Related CN1985851B (en) | 2006-08-07 | 2006-08-07 | Lipoid microsphere injection containing toad cake extract and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1985851B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526111A (en) * | 2012-02-06 | 2012-07-04 | 华南农业大学 | Slow-release microsphere containing venenum bufonis lipoclastic substances as well as preparation method and application thereof |
| CN103191156A (en) * | 2012-01-05 | 2013-07-10 | 韦旭斌 | Toad venom sustained-release injection fluid and preparation method thereof |
| CN104337844A (en) * | 2013-08-02 | 2015-02-11 | 北京因科瑞斯医药科技有限公司 | Venenum bufonis extractive and application of preparation of venenum bufonis extractive to preparing medicines for treating melanoma |
| CN104758248A (en) * | 2015-04-23 | 2015-07-08 | 合肥华方医药科技有限公司 | Total bufogenin nano-lipid microsphere injection and preparation method thereof |
| CN105125592A (en) * | 2015-10-12 | 2015-12-09 | 北京诺康达医药科技有限公司 | Medicine containing toad venom lipid-soluble substances and preparation method thereof |
| CN105477020A (en) * | 2015-06-17 | 2016-04-13 | 赵婷 | Anti-glioma drugs based on Venenum Bufonis extract and preparation method thereof |
| CN112807248A (en) * | 2020-12-31 | 2021-05-18 | 海南大学 | Coconut oil nanosphere and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1290489C (en) * | 2004-01-29 | 2006-12-20 | 上海现代药物制剂工程研究中心有限公司 | Toad extract liposome preparation for injection and its preparing method |
-
2006
- 2006-08-07 CN CN2006100474037A patent/CN1985851B/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103191156A (en) * | 2012-01-05 | 2013-07-10 | 韦旭斌 | Toad venom sustained-release injection fluid and preparation method thereof |
| CN102526111A (en) * | 2012-02-06 | 2012-07-04 | 华南农业大学 | Slow-release microsphere containing venenum bufonis lipoclastic substances as well as preparation method and application thereof |
| CN104337844A (en) * | 2013-08-02 | 2015-02-11 | 北京因科瑞斯医药科技有限公司 | Venenum bufonis extractive and application of preparation of venenum bufonis extractive to preparing medicines for treating melanoma |
| CN104758248A (en) * | 2015-04-23 | 2015-07-08 | 合肥华方医药科技有限公司 | Total bufogenin nano-lipid microsphere injection and preparation method thereof |
| CN105477020A (en) * | 2015-06-17 | 2016-04-13 | 赵婷 | Anti-glioma drugs based on Venenum Bufonis extract and preparation method thereof |
| CN105125592A (en) * | 2015-10-12 | 2015-12-09 | 北京诺康达医药科技有限公司 | Medicine containing toad venom lipid-soluble substances and preparation method thereof |
| CN112807248A (en) * | 2020-12-31 | 2021-05-18 | 海南大学 | Coconut oil nanosphere and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1985851B (en) | 2012-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105434337A (en) | Propranolol hydrochloride submicron emulsion gel and preparation method and application thereof | |
| CN112912066A (en) | Nimodipine injection composition and preparation method thereof | |
| Wang et al. | Chitosan-based food-grade Pickering emulsion loading with Rosa roxburghii extract against precancerous lesions of gastric carcinoma | |
| CN105125592A (en) | Medicine containing toad venom lipid-soluble substances and preparation method thereof | |
| CN1985851B (en) | Lipoid microsphere injection containing toad cake extract and its preparing method | |
| CN102552137B (en) | Triptolide fat emulsion injection and preparation method thereof | |
| CN100375621C (en) | Vinorelbine liposome micro ball injection and its prepn | |
| CN102349944A (en) | Nasal thermosensitive in-situ gel prepared by radix scutellariae extract, its preparation method and its application | |
| CN101006997B (en) | Compound taxol and its derivative docetaxel fat emulsion and preparation method | |
| CN109364023A (en) | A kind of Aprepitant intravenous injection emulsion and its preparation method and application | |
| CN100506225C (en) | Pharmaceutical use, medicine composition and preparation process of angelica oil components | |
| CN105311622B (en) | A kind of combination medicine that treating pain and its preparation, preparation method | |
| CN100493515C (en) | Nano emulsion containing ginsenoside, preparation method and usage | |
| CN102631400A (en) | Compound minoxidil nano-emulsion antihypertensive medicament | |
| CN103006681B (en) | Compound emulsifiable paste for treating acne and preparation method thereof | |
| CN101953785B (en) | Myricetin microemulsion type preparation and preparation method thereof | |
| CN101491550A (en) | Compound preparation of red yeast rice extract and coenzyme Q10 and preparation method thereof | |
| CN102920657B (en) | 16-pregnadiene alcohol ketone submicron emulsion injection and preparation method thereof | |
| CN101485632A (en) | Nimodipine lipid microsphere injection and preparation method thereof | |
| CN1294990C (en) | Composition of nanometer SOD and ginseng or its extract and its preparation method | |
| CN109260149B (en) | Nano emulsion containing gamma-tocotrienol and preparation method and application thereof | |
| CN100525753C (en) | Coenzyme Q10Submicron emulsion injection and preparation method thereof | |
| CN106137959A (en) | A kind of compound recipe Quercetin nanoemulsion antisenescence health product | |
| CN106214635A (en) | A kind of Fluorouracil Injection pharmaceutical composition | |
| KR100524700B1 (en) | Pharmaceutical compositions for Hyperlipidemia treatment using of Self Emulsifying drug delivery system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120125 Termination date: 20160807 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |